|
Top : Drug Information : Antibiotics
CF Resources: Drug Information : Antibiotics
Links:
- Antibiotic--Cipro (2002)
- Cipro (ciprofloxacin hydrochloride)
Has been suspected in causing joint discomfort in some people.
Some say that when they take it on an empty stomach, it will give them nausea. If they eat, no nausea.
Some people that I know have been reporting sun sensitivity with this drug; be sure to wear sunscreen while on it. Otherwise, you may get a bad sunburn.
(Added: 23-Oct-2002 Hits: 115 Rating: 0 ) Rate It
- Inhaled antibiotics--TOBI (2002
- Introduced in 1998, TOBI is the first inhaled antibiotic approved for treating lung infections in CF patients caused by the Pseudomonas aeruginosa bacterium. Because TOBI is delivered directly to the lungs, the drug can be given at higher doses than would be safe to administer systemically
(Added: 23-Oct-2002 Hits: 97 Rating: 0 ) Rate It
- Israel Approves Tobi, Antibiotic For Lung Infections (2000)
- In Israel, Tobi will be distributed by Teva Pharmaceutical Industries Ltd. An estimated 400 people in Israel have cystic fibrosis, a serious genetic disease that primarily affects Caucasians. Tobi is designed for these patients to take at home in repeated cycles of 28 days on drug, 28 days off drug. It is inhaled twice daily and requires about 15 minutes each time.
(Added: 23-Oct-2002 Hits: 66 Rating: 0 ) Rate It
- Tobi Approved In Canada And Argentina For CF (1999)
- PathoGenesis Corp.’s Tobi(R) (tobramycin solution for inhalation) has received marketing clearance from regulatory authorities in Canada and Argentina for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infections. In Argentina, about 700 patients are treated at centralised cystic fibrosis centres.
(Added: 23-Oct-2002 Hits: 52 Rating: 0 ) Rate It
- Tobi Approved In Canada For Cystic Fibrosis (1999)
- Health Canada’s Therapeutic Products Programme has approved PathoGenesis Canada Ltd.’s Tobi(TM) (tobramycin solution for inhalation) for the management of cystic fibrosis (CF) patients with chronic pulmonary Pseudomonas aeruginosa infections.
P. aeruginosa bacteria are responsible for nearly 90 percent of all lung infections in CF patients.
(Added: 23-Oct-2002 Hits: 57 Rating: 0 ) Rate It
- Tobramycin (added 2002)
- TOBI is indicated for the management of cystic fibrosis patients with P. aeruginosa .
Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia
(Added: 23-Oct-2002 Hits: 47 Rating: 0 ) Rate It
- Two-Year Data on TOBI (1999)
- "The two-year adolescent data are particularly exciting, because the
results suggest that TOBI can modify the course of the disease"
"The data show that chronic intermittent therapy with TOBI
maintains benefits to patients for at least 96 weeks."
(Added: 23-Oct-2002 Hits: 73 Rating: 0 ) Rate It
- Zithromax/azithromycin
- Azithromycin is indicated for the treatment of patients with mild to moderate infections (special conditions)
(Added: 1-Dec-2002 Hits: 131 Rating: 0 ) Rate It
Pages Updated On: 27-Sep-2005 - 04:46:50
Links Engine 2.0 By: Gossamer Threads Inc.
The Cystic Fibrosis-Reaching Out Foundation is a non-profit Foundation under Section 501 (c) 3 of the Internal Revenue Code. Accordingly, the Foundation is not required to pay income taxes. Donors may deduct contributions to the Cystic Fibrosis-Reaching Out Foundation Inc, only to the extent that their contributions are gifts, with no consideration given.
|
